- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06169436
Translational Cancer Observational Protocol
December 5, 2023 updated by: Francesco Montorsi, IRCCS San Raffaele
2014 Transizionali - Observational Study on the Occurrence of Relapses and on the Quality of Life in Patients Who Underwent Nephroureterectomy Surgery
Observational study on relapse occurrence and on the quality of life in patients who underwent nephroureterectomy surgery
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Monocentric prospective and retrospective observational study on the quality of life and on the pathological status in patients who underwent nephroureterectomy surgery.
Oncological, psychological, sexual and quality of life-related data will be collected within a specifically created database that will allow us an easy and secure data extraction for the statistical analysis required by the clinical trial in terms of oncological relapse, clinical progression and improve the assistance and therapeutic strategy for each patient.
Retrospective data for patients who underwent surgery between 1987 and today will be available in the form of clinical report stored in the hospital archives.
Study Type
Observational
Enrollment (Estimated)
1250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Francesco Montorsi, MD.
- Phone Number: 02 2643 7286
- Email: montorsi.francesco@hsr.it
Study Contact Backup
- Name: Francesco Fiorio, MSC
- Phone Number: 02 2643 6268
- Email: fiorio.francesco@hsr.it
Study Locations
-
-
MI
-
Milan, MI, Italy, 20132
- Recruiting
- IRCCS Ospedale San Raffaele
-
Contact:
- Francesco Fiorio, MSC
- Phone Number: 02 2643 6268
- Email: fiorio.francesco@hsr.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with upper tract urothelial cancer who underwent nephroureterectomy surgery.
Description
Inclusion Criteria:
- 18 years or older
- Upper tract urothelial cancer diagnosis
- Indication to cancer removal through nephroureterectomy surgery
- Ability to read and sign the informed consent
Exclusion Criteria:
- Age < 18 years
- Absence of upper tract urothelial cancer
- Inability to read and sign the informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Experimental
Patients with upper urinary tract urothelial cancer who underwent nephroureterectomy surgery
|
Removal of cancer mass by urether and kidney complete resection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical progression data collection
Time Frame: 50 years
|
Collection intended for the purpose of implementing diagnostic and therepautic strategies for the management of the disease in both the patient enrolled in the study and for future cases.
Data will be collected in a dedicated internal database by means of medical records obtained during the patients' stay in the hospital and during follow up visits.
The data collected includes anamnesis, data regarding surgery, laboratory exam and imaging exams.
|
50 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Francesco Montorsi, MD, IRCCS Ospedale San Raffaele
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 17, 2014
Primary Completion (Estimated)
July 17, 2064
Study Completion (Estimated)
July 17, 2064
Study Registration Dates
First Submitted
November 23, 2023
First Submitted That Met QC Criteria
December 5, 2023
First Posted (Estimated)
December 13, 2023
Study Record Updates
Last Update Posted (Estimated)
December 13, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Ureteral Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Neoplasms
- Carcinoma, Transitional Cell
- Ureteral Neoplasms
Other Study ID Numbers
- 2014 - Transizionali
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Urinary Tract Urothelial Carcinoma
-
Changhai HospitalActive, not recruitingNeoadjuvant Therapy | Urothelial Carcinoma Ureter | Upper Urinary Tract Urothelial CarcinomaChina
-
RenJi HospitalNot yet recruitingUpper Urinary Tract Urothelial CarcinomaChina
-
Peking University First HospitalNot yet recruitingUpper Tract Urothelial Carcinoma | Upper Tract Urothelial Carcinoma Receiving Kidney-sparing TherapyChina
-
RenJi HospitalCompletedNeoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial CarcinomaChina
-
Chinese University of Hong KongNot yet recruitingUpper Tract Urothelial CarcinomaHong Kong
-
Peking University First HospitalRemeGen Co., Ltd.Not yet recruitingUpper Tract Urothelial CarcinomaChina
-
RenJi HospitalPeking University First Hospital; West China Hospital; Tianjin Medical University...Not yet recruitingUpper Tract Urothelial CarcinomaChina
-
Samsung Medical CenterRecruitingUpper Tract Urothelial CarcinomaSouth Korea
-
UroGen Pharma Ltd.RecruitingUrothelial Carcinoma | Upper Urinary Tract Urothelial CarcinomaUnited States, Spain, Israel, Bulgaria, Georgia, Poland, Romania, Hungary
-
Tyra Biosciences, IncRecruitingLow Grade Upper Tract Urothelial CarcinomaUnited States
Clinical Trials on Nephroureterectomy
-
Zealand University HospitalSuspended
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedCancer of the Urinary TractUnited States
-
Peking University First HospitalRecruiting
-
Seoul National University HospitalUnknownUrothelial CarcinomaKorea, Republic of
-
Xiangya Hospital of Central South UniversityHunan Cancer Hospital; The Third Xiangya Hospital of Central South University; Hunan Provincial People's Hospital and other collaboratorsCompletedHigh-Grade Upper Tract Urothelial CarcinomaChina
-
Peking University Third HospitalBeijing Friendship Hospital; Peking University Cancer Hospital & Institute; The... and other collaboratorsNot yet recruitingUpper Tract Urothelial CarcinomaChina
-
Case Comprehensive Cancer CenterRecruitingUrothelial CarcinomaUnited States
-
Tianjin Medical University Second HospitalRecruitingNeoadjuvant Therapy | PD-1 Inhibitor | Upper Tract Urothelial Carcinoma | Nab-paclitaxelChina
-
University of ReadingINNOPURERecruitingAutismUnited Kingdom
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Seagen Inc.RecruitingRenal Pelvis and Ureter Urothelial CarcinomaUnited States